Clinical Trial Update: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anti-IL-5 therapy for bullous pemphigoid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Anti-IL-5 therapy

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Pemphigoid, Bullous | Phase 2 | Status: COMPLETED